Shanghai GeneChem Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Shanghai China (2002)

Organization Overview

First Clinical Trial
2016
NCT02672501
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (5)

cd19 car-t cells (2 trials)

cea car-t cells (1 trial)

gpc3 car-t cell (3 trials)

mesothelin car t cells (2 trials)

mg7-cart (1 trial)

Drugs in Phase 1 Trials (1)

cyclophosphamide (cytoxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Liver Neoplasms (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 6